Physician profile
Addie Dissick
NPI 1477700698
$16,385.61
in general payments reported to CMS, 2019-2025
18 companies · $6,327 in 2025
The $6,327 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,930 · 2020: $98.98 · 2021: $754 · 2022: $1,747 · 2023: $1,522 · 2024: $2,008 · 2025: $6,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,831 · Consulting Fee: $2,280 · Travel and Lodging: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,831.43 |
| Consulting Fee | $2,280.00 |
| Travel and Lodging | $744.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,265.96 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $3,672.42 | 2021-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,759.19 | 2019-2025 | |
| Horizon Therapeutics Plc | $965.36 | 2019-2023 | Krystexxa |
| Pfizer INC. | $807.26 | 2019-2025 | |
| Novo Nordisk INC | $540.24 | 2023-2025 | Wegovy |
| Glaxosmithkline, LLC. | $367.23 | 2021-2025 | Benlysta |
| Amgen INC. | $323.79 | 2024-2025 | Evenity, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $186.10 | 2022-2025 | Saphnelo |
| Ucb, INC. | $122.20 | 2025 | Bimzelx |
| Phathom Pharmaceuticals, INC. | $108.19 | 2024 | Voquezna |
| Mallinckrodt Hospital Products INC. | $68.82 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $48.14 | 2021-2022 | |
| Depuy Synthes Sales INC. | $45.88 | 2021-2024 | Orthovisc, Monovisc |
| Medtronic USA, INC. | $36.43 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $35.56 | 2025 | |
| Octapharma USA, INC. | $17.22 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2024 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addie Dissick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.